Ax­some's ap­proved de­pres­sion drug clears Alzheimer's ag­i­ta­tion tri­al months af­ter Lund­beck-Ot­su­ka duo

Af­ter an Au­gust ap­proval for treat­ing ma­jor de­pres­sive dis­or­der, Ax­some Ther­a­peu­tics’ tablet for­mu­la­tion of a cough sup­pres­sant and an­ti­de­pres­sant has now cleared a Phase III …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER